Psychedelics Biotech Startup Launches Phase 1 Study On Ayahuasca's Active Ingredient | Benzinga IgniteIt Cannabis (formerly Benzinga Cannabis) Entheon Biomedical benzinga.com/markets/cannab…

It's been another big week in #psychedelic business news, with a new ETF launching, and regulatory and financial updates from Mydecine Innovations Group, Entheon Biomedical, and Small Pharma. Read our full roundup here: ow.ly/QFm650HMQWn #business #stocks #etfs #finance #psychedelics

This is my most up-to-date talk online. So fresh in fact, that I forgot to add the references to my brand new slide at 37mins! I've since found new relevant refs on modularity. Expect to hear more about the M word & psychedelics very soon. Maybe a new splash is coming.

.Entheon Biomedical has received approval for its trial which will form the basis for future Phase II trial exploring #DMT for #SmokingCessation and the treatment of other #SubstanceAddictions. #Addiction #ClinicalTrials #Europe #PsychedelicResearch psychedelichealth.co.uk/2022/02/07/eur…

.Natán Ponieman's Psyched is LIVE on Benzinga Filament Health @ElementalAdvis1 $PSYK CybinInc Health Canada and PHAC Entheon Biomedical and much more! cc. JasonRaznick benzinga.com/markets/cannab…

Here is a #weekly roundup of #news items from the #psychedelics industry 🍄🍄 Entheon Biomedical, Psyched Wellness, Pharmadrug | CSE: PHRX, Mydecine Innovations Group, PharmaTher Holdings Ltd., Filament Health, Small Pharma $ENBI $PSYC $PHRX $MYCO $PHRM $PHRRF $FH $FLHLF $DMT $DMTTF bit.ly/3uBn3Hk

#DMT 101: A Molecular #Masterclass by Entheon Biomedical's CSO & DOO, Andrew Hegle Entheon Biomedical $ENBI $ENTBF bit.ly/3CGxn1q

Big news! We've published our 1-year follow-up of our trial of #psilocybin for depression. The massive decreases in depression were unshaken a year later. Mystical experience in the session was related to improved well-being a year later. Great thread by 1st author Natalie Gukasyan, MD

We are thrilled to be collaborating with wavepaths on our upcoming trial, EBRX-101. Their cutting-edge adaptive music platform will be implemented for participants undergoing ketamine therapy for treatment-resistant major depressive disorder. Read here: hubs.li/Q014f-Xy0

$ENBI Entheon Biomedical is launching the upcoming EBIQ-101 Observational Trial in partnership with wavepaths. The study is taking place at Heading Health. Recruitment for EBIQ-101 has been completed & first patient dose is scheduled this week. #DMT #music bit.ly/3rSb5r2

The push for medical #DMT is on. Truffle Report looks at top corporate and scientific developments involving the spirit molecule from MindMed, Algernon Pharmaceuticals, Entheon Biomedical, Small Pharma and more. Full article here: ow.ly/khee50HXOHz #science #business #medicine

Join us on February 24th, meet & connect others across Canada who are inspired by psychedelic medicines. 4 pm PST. ✨ RSVP: bit.ly/3rEXNOL

#ARCtalk | We love celebrating milestones. How long have you or a loved one been in recovery? Let us know!

In this article for Addiction Pro, Entheon's CEO writes about his impetus for founding the company, the commitment to developing evidence-based treatments for addiction disorder through psychedelic drug research and development, and why focusing on #DMT. hubs.li/Q014JK880

The First-Ever Clinical Trial For DMT Use In Major Depressive Disorder Show Promise The Dales Report buff.ly/3HiDawa

Glad to announce that our Observational Study, EBIQ-101 is progressing as planned with first-patient dose having recently taken place. Read the full news release here: hubs.li/Q014Qjmy0

Learn how your genetics can impact your psychedelic response. We provide rapid DNA test results within days. You’ll also get access to pre-screening surveys and educational resources to help you gain key insights into your psychedelic journey. #psychedelics #genetictesting

Download ASAM's New Guide: Integrating Tobacco Use Disorder Interventions in Addiction Treatment. Learn providing how evidence based tobacco treatment during addiction treatment increases the likelihood of long term recovery. Download >>> ow.ly/saBw50HSclF. #iCOVIDQuit.

Registration is now open for our conference From Research to Reality: Global Summit on Psychedelic-Assisted Therapies and Medicine (R2R2022) in Toronto May 27-29! And our late-breaking abstract submission portal is open! Secure your spots now! mailchi.mp/863279a48112/c…

We are very proud to announce first-patient enrolment has completed in our Phase 1 study of DMT. Read the full news release here: hubs.li/Q015--160